What is the recommended acute management and treatment for Guillain‑Barré syndrome?

Acute Management and Treatment of Guillain-Barré Syndrome

Immediate Life-Threatening Assessment

Assess respiratory function and autonomic stability immediately upon presentation, as these determine mortality risk and need for ICU-level care. 1

• Measure vital capacity, negative inspiratory force (NIF), and maximum inspiratory/expiratory pressures at presentation and serially—approximately 20% of patients develop respiratory failure requiring mechanical ventilation, which can occur rapidly and sometimes without obvious dyspnea. 1, 2
• Apply the "20/30/40 rule": the patient is at risk of respiratory failure if vital capacity is <20 ml/kg, maximum inspiratory pressure is <30 cmH₂O, or maximum expiratory pressure is <40 cmH₂O. 1
• Perform electrocardiography and continuously monitor heart rate and blood pressure for arrhythmias and blood pressure instability, as cardiovascular complications contribute to 3–10% mortality even with optimal care. 1, 2
• Admit patients with severe weakness limiting self-care, dysphagia, facial or respiratory muscle weakness, or rapidly progressive symptoms to an inpatient unit capable of rapid ICU transfer. 1

Diagnostic Workup (Do Not Delay Treatment)

Obtain an immediate neurology consultation for every suspected case of GBS and initiate treatment based on clinical suspicion—do not wait for antibody test results or complete diagnostic workup. 1, 3

• Perform lumbar puncture to look for albumino-cytological dissociation (elevated protein with normal cell count); however, do not dismiss GBS based on normal CSF protein in the first week, as this finding may be absent early in the disease course. 1, 3
• Conduct nerve conduction studies and electromyography to support the diagnosis and classify the neuropathy pattern (demyelinating vs. axonal); repeat after 2–3 weeks if initial studies are normal or equivocal. 1, 3
• Order MRI of the spine with contrast to exclude compressive lesions and assess for nerve root enhancement or thickening. 1
• Test serum antiganglioside antibodies (e.g., anti-GQ1b) when Miller Fisher syndrome is suspected (ophthalmoplegia, ataxia, areflexia), but recognize that approximately 63% of all GBS patients lack detectable antibodies—negative results do not exclude the diagnosis. 1

First-Line Immunotherapy

Initiate intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 consecutive days (total dose 2 g/kg) for any patient unable to walk unaided within 2–4 weeks of symptom onset. 1, 3, 4

• IVIg is the preferred first-line therapy because it is easier to administer, more widely available, achieves higher treatment-completion rates, and requires no special equipment or vascular access compared to plasma exchange. 1, 3
• Plasma exchange (200–250 ml/kg over 4–5 sessions) is an equally effective alternative when IVIg is contraindicated, not tolerated, or unavailable; however, it requires specialized equipment, central venous access, and is associated with higher complication rates. 1, 3, 5
• Do not use corticosteroids alone for idiopathic GBS—randomized controlled trials have shown no benefit, and the EAN/PNS guideline recommends against both oral and IV corticosteroids. 1, 3, 6
• Do not use sequential therapy (plasma exchange followed immediately by IVIg or vice versa)—this approach has not shown benefit over either treatment alone. 1, 3

Special Situation: Immune Checkpoint Inhibitor–Related GBS

• Permanently discontinue the immune checkpoint inhibitor immediately when GBS is diagnosed. 1
• Add concurrent corticosteroids (methylprednisolone 2–4 mg/kg/day) to IVIg or plasma exchange in checkpoint inhibitor–related GBS. 1
• For Grade 3–4 severity, consider pulse corticosteroid therapy (methylprednisolone 1 g/day for 5 days) as an adjunct. 1

Expected Treatment Response and Management of Fluctuations

Approximately 40% of patients do not improve in the first 4 weeks following treatment—this does not necessarily mean treatment failed, as progression might have been worse without therapy. 1, 7

• Treatment-related fluctuations (TRFs) occur in 6–10% of patients, defined as disease progression within 2 months after initial treatment-induced improvement or stabilization. 1, 7, 3
• Repeating a full course of IVIg (0.4 g/kg/day for 5 days) or plasma exchange is common practice for TRFs, although high-quality evidence supporting this approach is lacking. 1, 7
• Do not repeat treatment before allowing 4 weeks for initial response, as natural recovery patterns in GBS can be slow. 7
• Consider changing the diagnosis to acute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) if progression continues after 8 weeks from onset or if the patient has three or more TRFs—this occurs in approximately 5% of patients initially diagnosed with GBS. 1, 3

Supportive Care and Complication Management

Perform daily neurologic examinations and serial pulmonary function assessments (vital capacity, NIF) throughout the acute phase. 1

• Monitor continuously for autonomic dysfunction including blood pressure/heart rate instability, pupillary dysfunction, and bowel/bladder dysfunction—dysautonomia is common and can be life-threatening. 1, 2
• Use gabapentinoids (gabapentin or pregabalin) or duloxetine for neuropathic pain—these agents can be started concurrently with IVIg without drug interaction. 1, 3
• Assess swallowing and coughing ability to identify aspiration risk; protect corneas from ulceration in patients with facial palsy and impaired eye closure. 1, 2
• Provide standard preventive measures for pressure ulcers, hospital-acquired infections, and deep vein thrombosis. 1
• Avoid medications that can worsen neuromuscular transmission: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides. 1

Prognosis and Long-Term Management

Approximately 80% of patients regain independent walking ability at 6 months, but recovery can continue for more than 3 years, with improvements possible even beyond 5 years. 1, 3, 8

• Overall mortality ranges from 3–10%, primarily due to cardiovascular and respiratory complications occurring in both acute and recovery phases. 1, 2, 8
• Advanced age and severe disease at onset are risk factors for poor outcome. 1, 8
• Arrange a structured rehabilitation program involving physiotherapists, occupational therapists, and rehabilitation specialists as soon as the patient is medically stable. 1
• Exercise programs (range-of-motion, stationary cycling, walking, strength training) improve physical fitness, walking ability, and independence in activities of daily living, but intensity must be monitored to avoid fatigue. 1
• Fatigue affects 60–80% of survivors and is a major disabling symptom; severe pain persists in at least one-third of patients at 1 year and may continue for a decade or more. 1
• Recurrence is uncommon (2–5% of patients) but higher than the background lifetime risk (0.1%); prior GBS is not an absolute contraindication to vaccination, but vaccination within one year of a GBS episode should be discussed with specialists. 1